Newer Treatment Approaches in Pediatric-Onset Multiple Sclerosis

  • Gabrielle Macaron
  • Jenny Feng
  • Manikum Moodley
  • Mary RenselEmail author
Multiple Sclerosis and Related Disorders (J Graves, Section Editor)
Part of the following topical collections:
  1. Topical Collection on Multiple Sclerosis and Related Disorders


Purpose of review

With the recognition that pediatric-onset multiple sclerosis (POMS) is characterized by more prominent disease activity, earlier age at onset of disability milestones, and more prominent cognitive impairment compared with physical disability earlier in the disease course compared with adult-onset multiple sclerosis (AOMS), there has been increasing interest in identifying optimal and safe treatment approaches to achieve better disease control in this group. Injectable therapies have been traditionally used as first line in this population, although not formally approved. This review focuses on current treatment and monitoring approaches in POMS.

Recent findings

In the past few years, and despite the paucity of FDA-approved medications for use in POMS, an increasing trend toward using newer disease-modifying therapies (DMTs) in this group is observed. However, escalation (as opposed to induction) remains the most frequent approach, and many children continue to be untreated before age 18, particularly before age 12. The only FDA- and EMA-approved disease-modifying therapy in POMS is fingolimod; however, dimethyl fumarate, teriflunomide, natalizumab, ocrelizumab, and alemtuzumab either have been evaluated in observational studies or are being currently investigated in formal randomized controlled trials for use in POMS and appear to be safe in this group. Autologous hematopoietic stem cell transplantation has also been evaluated in a small series. Clinical outcome measures and MS biomarkers have been poorly studied in POMS; however, the use of composite functional scores, neurofilament light chain, optical coherence tomography, and imaging findings is being increasingly investigated to improve early diagnosis and efficient monitoring of POMS.


Off-label use of newer DMTs in POMS is increasing, and based on retrospective data, and phase 2 trials, this approach appears to be safe in children. Results from ongoing trials will help clarify the safety and efficacy of these therapies in the future. Fingolimod is the only FDA-approved medication for use in POMS. Outcome measures and biomarkers used in AOMS are being studied in POMS and are greatly needed to quantify treatment response in this group.


Multiple sclerosis Pediatric Treatment Outcome measures Safety Efficacy 


Compliance with Ethical Standards

Conflict of Interest

Gabrielle Macaron receives fellowship funding from the National Multiple Sclerosis Society Institutional Clinician Training Award ICT 0002 and has received fellowship funding from Biogen Fellowship Grant 6873-P-FEL. She has served on a scientific advisory board for Genentech.

Jenny Feng receives funding via a Sylvia Lawry Physician Fellowship Grant through the National Multiple Sclerosis Society (No. FP-1707-28768). She has served on scientific advisory board for Sanofi.

Manikum Moodley receives funding from the National Multiple Sclerosis Society.

Mary Rensel serves as a consultant or speaker for Biogen, Teva, Genzyme, and Novartis. She receives grant funding from the National Multiple Sclerosis Society. She also serves on the advisory board for Serono and received research support from MedImmune and Genentech.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Renoux C, Vukusic S, Mikaeloff Y, Edan G, Clanet M, Dubois B, et al. Natural history of multiple sclerosis with childhood onset. N Engl J Med. 2007;356(25):2603–13.PubMedGoogle Scholar
  2. 2.
    • Bar-Or A, Hintzen RQ, Dale RC, Rostasy K, Brück W, Chitnis T. Immunopathophysiology of pediatric CNS inflammatory demyelinating diseases. Neurology. 2016;87(9):S12–9 Recent comprehensive review on the physiopathology of pediatric-onset demyelinating diseases.PubMedGoogle Scholar
  3. 3.
    Regulations requiring manufacturers to assess the safety and effectiveness of new drugs and biological products in pediatric patients--FDA. Final rule. Fed Regist. 1998;63(231):66631–72.Google Scholar
  4. 4.
    Steinbrook R. Testing medications in children. N Engl J Med. 2002;347:1462–70.PubMedGoogle Scholar
  5. 5.
    Chitnis T. Disease-modifying therapy of pediatric multiple sclerosis. Neurotherapeutics. 2013;10(1):89–96.PubMedGoogle Scholar
  6. 6.
    Ghezzi A. Randomized clinical trials (RCTs) in pediatric multiple sclerosis: are they really necessary? Mult Scler. 2017;23(7):1042–3.PubMedGoogle Scholar
  7. 7.
    •• Krysko KM, Graves J, Rensel M, Weinstock-Guttman B, Aaen G, Benson L, et al. Use of newer disease-modifying therapies in pediatric multiple sclerosis in the US. Neurology. 2018;91(19):e1778–87 Important analysis on trends in using newer disease-modifying therapies in pediatric-onset multiple sclerosis.PubMedPubMedCentralGoogle Scholar
  8. 8.
    Mikaeloff Y, Caridade G, Tardieu M, Suissa S. Effectiveness of early beta interferon on the first attack after confirmed multiple sclerosis: a comparative cohort study. Eur J Paediatr Neurol. 2008;12(3):205–9.PubMedGoogle Scholar
  9. 9.
    Banwell B, Schelensky L, Reder AT, Antonijevic I, Alexey B, Eraksoy M, et al. Safety and tolerability of interferon beta-1b in pediatric multiple sclerosis. Neurology. 2006;66(4):472–6.PubMedGoogle Scholar
  10. 10.
    Krupp LB, Pohl D, Ghezzi A, Boyko A, Tenembaum S, Chen L, et al. Subcutaneous interferon β-1a in pediatric patients with multiple sclerosis: regional differences in clinical features, disease management, and treatment outcomes in an international retrospective study. J Neurol Sci. 2016;363:33–8.PubMedGoogle Scholar
  11. 11.
    Mikaeloff Y, Moreau T, Debouverie M, Pelletier J, Lebrun C, Gout O, et al. Interferon-beta treatment in patients with childhood-onset multiple sclerosis. J Pediatr. 2001;139(3):443–6.PubMedGoogle Scholar
  12. 12.
    Tenembaum SN, Segura MJ. Interferon beta-1a treatment in childhood and juvenile-onset multiple sclerosis. Neurology. 2006;67(3):511–3.PubMedGoogle Scholar
  13. 13.
    Pohl D, Rostasy K, Gärtner J, Hanefeld F. Treatment of early onset multiple sclerosis with subcutaneous interferon beta-1a. Neurology. 2005;64(5):888–90.PubMedGoogle Scholar
  14. 14.
    Kornek B, Bernert G, Balassy C, Geldner J, Prayer D, Feucht M. Glatiramer acetate treatment in patients with childhood and juvenile onset multiple sclerosis. Neuropediatrics. 2003;34(3):120–6.PubMedGoogle Scholar
  15. 15.
    •• McGinley M, Rossman IT. Bringing the HEET: the argument for high-efficacy early treatment for pediatric-onset multiple sclerosis. Neurotherapeutics. 2017;14(4):985–98 Discussion on escalation vs. induction approach in pediatric-onset multiple sclerosis.PubMedPubMedCentralGoogle Scholar
  16. 16.
    • Brown JWL, Coles A, Horakova D, Havrdova E, Izquierdo G, Prat A, et al. Association of initial disease-modifying therapy with later conversion to secondary progressive multiple sclerosis. JAMA. 2019;321(2):175–87 Recent publication on the potential benefit of induction approach on long-term outcomes in adults with multiple sclerosis.PubMedPubMedCentralGoogle Scholar
  17. 17.
    Bevan C, Cree BA. Disease activity free status: a new end point for a new era in multiple sclerosis clinical research? JAMA Neurol. 2014;71(3):269–70.PubMedGoogle Scholar
  18. 18.
    Gorman MP, Healy BC, Polgar-Turcsanyi M, Chitnis T. Increased relapse rate in pediatric-onset compared with adult-onset multiple sclerosis. Arch Neurol. 2009;66(1):54–9.PubMedGoogle Scholar
  19. 19.
    Benson LA, Healy BC, Gorman MP, Baruch NF, Gholipour T, Musallam A, et al. Elevated relapse rates in pediatric compared to adult MS persist for at least 6 years. Mult Scler Relat Disord. 2014;3(2):186–93.PubMedGoogle Scholar
  20. 20.
    Harding KE, Liang K, Cossburn MD, Ingram G, Hirst CL, Pickersgill TP, et al. Long-term outcome of paediatric-onset multiple sclerosis: a population-based study. J Neurol Neurosurg Psychiatry. 2013;84(2):141–7.PubMedGoogle Scholar
  21. 21.
    Amato MP, Goretti B, Ghezzi A, Lori S, Zipoli V, Moiola L, et al. Cognitive and psychosocial features in childhood and juvenile MS: two-year follow-up. Neurology. 2010;75(13):1134–40.PubMedGoogle Scholar
  22. 22.
    •• Ruano L, Branco M, Portaccio E, Goretti B, Niccolai C, Patti F, et al. Patients with paediatric-onset multiple sclerosis are at higher risk of cognitive impairment in adulthood: an Italian collaborative study. Mult Scler. 2018;24(9):1234–42 Recent study on the prevalence of cognitive impairment in pediatric multiple sclerosis compared with adult multiple sclerosis.PubMedGoogle Scholar
  23. 23.
    Alroughani R, Ahmed SF, Al-Hashel J. Pediatric-onset multiple sclerosis disease progression in Kuwait: a retrospective analysis. Pediatr Neurol. 2015;53(6):508–12.PubMedGoogle Scholar
  24. 24.
    •• Huppke P, Huppke B, Ellenberger D, Rostasy K, Hummel H, Stark W, et al. Therapy of highly active pediatric multiple sclerosis. Mult Scler J. 2019;25(1):72–80 Important paper on the prevalence of highly active disease in pediatric multiple sclerosis and benefit of natalizumab and fingolimod in this group.Google Scholar
  25. 25.
    Yeh EA, Weinstock-Guttman B, Ramanathan M, Ramasamy DP, Willis L, Cox JL, et al. Magnetic resonance imaging characteristics of children and adults with paediatric-onset multiple sclerosis. Brain. 2009;132(Pt 12):3392–400.PubMedGoogle Scholar
  26. 26.
    Pfeifenbring S, Bunyan RF, Metz I, Rover C, Huppke P, Gartner J, et al. Extensive acute axonal damage in pediatric multiple sclerosis lesions. Ann Neurol. 2015;77(4):655–67.PubMedPubMedCentralGoogle Scholar
  27. 27.
    Kerbrat A, Aubert-Broche B, Fonov V, Narayanan S, Sled JG, Arnold DA, et al. Reduced head and brain size for age and disproportionately smaller thalami in child-onset MS. Neurology. 2012;78(3):194–201.PubMedGoogle Scholar
  28. 28.
    Rieckmann P. Concepts of induction and escalation therapy in multiple sclerosis. J Neurol Sci. 2009;277(S1):S42–5.PubMedGoogle Scholar
  29. 29.
    Chitnis T, Tenembaum S, Banwell B, Krupp L, Pohl D, Rostasy K, et al. Consensus statement: evaluation of new and existing therapeutics for pediatric multiple sclerosis. Mult Scler. 2012 Jan;18(1):116–27.PubMedGoogle Scholar
  30. 30.
    • Wassmer E, Chitnis T, Pohl D, Amato MP, Banwell B, Ghezzi A, et al. International Pediatric MS Study Group Global Members Symposium report. Neurology. 2016;87(9):S110–6 Expert consensus on advances and challenges in the diagnosis and management of pediatric multiple sclerosis and other neuroinflammatory CNS disorders.PubMedGoogle Scholar
  31. 31.
    • Chitnis T, Ghezzi A, Bajer-Kornek B, Boyko A, Giovannoni G, Pohl D. Pediatric multiple sclerosis: escalation and emerging treatments. Neurology. 2016;87(S2):S103–9 Review on different treatment approaches and evidence in pediatric multiple sclerosis.PubMedGoogle Scholar
  32. 32.
    Food and Drug Association. Press Announcements - FDA expands approval of Gilenya to treat multiple sclerosis in pediatric patients. Office of the Commissioner; 2018 [cited 2019 Mar 31]. Available from:
  33. 33.
    Pakdaman H, Fallah A, Sahraian MA, Pakdaman R, Meysamie A. Treatment of early onset multiple sclerosis with suboptimal dose of interferon beta-1a. Neuropediatrics. 2006;37(4):257–60.PubMedGoogle Scholar
  34. 34.
    Ghezzi A, Amato MP, Capobianco M, Gallo P, Marrosu G, Martinelli V, et al. Disease-modifying drugs in childhood-juvenile multiple sclerosis: results of an Italian co-operative study. Mult Scler. 2005;11(4):420–4.PubMedGoogle Scholar
  35. 35.
    Tenembaum SN, Banwell B, Pohl D, Krupp LB, Boyko A, Meinel M, et al. Subcutaneous interferon beta-1a in pediatric multiple sclerosis: a retrospective study. J Child Neurol. 2013;28(7):849–56.PubMedGoogle Scholar
  36. 36.
    Ghezzi A, Amato MP, Annovazzi P, Capobianco M, Gallo P, La Mantia L, et al. Long-term results of immunomodulatory treatment in children and adolescents with multiple sclerosis: the Italian experience. Neurol Sci. 2009;30(3):193–9.PubMedGoogle Scholar
  37. 37.
    Gorman MP, Tillema J-M, Ciliax AM, Guttmann CRG, Chitnis T. Daclizumab use in patients with pediatric multiple sclerosis. Arch Neurol. 2012;69(1):78–81.PubMedGoogle Scholar
  38. 38.
    Alroughani R, Das R, Penner N, Pultz J, Taylor C, Eraly S. Safety and efficacy of delayed-release dimethyl fumarate in pediatric patients with relapsing multiple sclerosis (FOCUS). Pediatr Neurol. 2018;83:19–24.PubMedGoogle Scholar
  39. 39.
    Fox RJ, Miller DH, Phillips JT, Hutchinson M, Havrdova E, Kita M, et al. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N Engl J Med. 2012;367(12):1087–97.PubMedGoogle Scholar
  40. 40.
    Rossman I, Moodley M, Rensel M. Dimethyl fumarate is well tolerated in a small cohort of pediatric-onset multiple sclerosis patients (P3.010). Neurology. 2016;86(16 Supplement):3.010.Google Scholar
  41. 41.
    Makhani N, Schreiner T. Oral dimethyl fumarate in children with multiple sclerosis: a dual-center study. Pediatr Neurol. 2016;57:101–4.PubMedGoogle Scholar
  42. 42.
    Fragoso YD, Alves-Leon SV, Barreira AA, Callegaro D, Brito Ferreira ML, Finkelsztejn A, et al. Fingolimod prescribed for the treatment of multiple sclerosis in patients younger than age 18 years. Pediatr Neurol. 2015;53(2):166–8.PubMedGoogle Scholar
  43. 43.
    •• Chitnis T, Arnold DL, Banwell B, Brück W, Ghezzi A, Giovannoni G, et al. Trial of fingolimod versus interferon beta-1a in pediatric multiple sclerosis. N Engl J Med. 2018;379(11):1017–27 Pivotal trial of fingolimod in pediatric multiple sclerosis, leading to FDA and EMA approval of this drug in children.PubMedGoogle Scholar
  44. 44.
    Kappos L, Radue E-W, O’Connor P, Polman CH, Hohlfeld R, Calabresi PA, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med. 2010;362(5):387–401.Google Scholar
  45. 45.
    Soelberg Sorensen P. Safety concerns and risk management of multiple sclerosis therapies. Acta Neurol Scand. 2017;136(3):168–86.PubMedGoogle Scholar
  46. 46.
    O’Connor P, Wolinsky JS, Confavreux C, Comi G, Kappos L, Olsson TP, et al. Randomized trial of oral teriflunomide for relapsing multiple sclerosis. N Engl J Med. 2011;365(14):1293–303.PubMedGoogle Scholar
  47. 47.
    Confavreux C, O’Connor P, Comi G, Freedman MS, Miller AE, Olsson TP, et al. Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomized, double-blind, placebo-controlled, phase 3 trial. Lancet Neurol. 2014;13(3):247–56.PubMedGoogle Scholar
  48. 48.
    Ghezzi A, Moiola L, Pozzilli C, Brescia-Morra V, Gallo P, Grimaldi LME, et al. Natalizumab in the pediatric MS population: results of the Italian registry. BMC Neurol. 2015;15:174.PubMedPubMedCentralGoogle Scholar
  49. 49.
    Ghezzi A, Pozzilli C, Grimaldi LME, Moiola L, Brescia-Morra V, Lugaresi A, et al. Natalizumab in pediatric multiple sclerosis: results of a cohort of 55 cases. Mult Scler. 2013;19(8):1106–12.PubMedGoogle Scholar
  50. 50.
    Kornek B, Aboul-Enein F, Rostasy K, Milos R-I, Steiner I, Penzien J, et al. Natalizumab therapy for highly active pediatric multiple sclerosis. JAMA Neurol. 2013;70(4):469–75.PubMedGoogle Scholar
  51. 51.
    Salzer J, Lycke J, Wickstrom R, Naver H, Piehl F, Svenningsson A. Rituximab in paediatric onset multiple sclerosis: a case series. J Neurol. 2016;263(2):322–6.PubMedGoogle Scholar
  52. 52.
    Beres SJ, Graves J, Waubant E. Rituximab use in pediatric central demyelinating disease. Pediatr Neurol. 2014;51(1):114–8.PubMedGoogle Scholar
  53. 53.
    Dale RC, Brilot F, Duffy LV, Twilt M, Waldman AT, Narula S, et al. Utility and safety of rituximab in pediatric autoimmune and inflammatory CNS disease. Neurology. 2014;83(2):142–50.PubMedPubMedCentralGoogle Scholar
  54. 54.
    Hauser SL, Bar-Or A, Comi G, Giovannoni G, Hartung H-P, Hemmer B, et al. Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis. N Engl J Med. 2017;376(3):221–34.PubMedGoogle Scholar
  55. 55.
    Montalban X, Hauser SL, Kappos L, Arnold DL, Bar-Or A, Comi G, et al. Ocrelizumab versus placebo in primary progressive multiple sclerosis. N Engl J Med. 2017;376(3):209–20.PubMedGoogle Scholar
  56. 56.
    Coles AJ, Twyman CL, Arnold DL, Cohen JA, Confavreux C, Fox EJ, et al. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomized controlled phase 3 trial. Lancet. 2012;380(9856):1829–1839.Google Scholar
  57. 57.
    Havrdova E, Arnold DL, Cohen JA, Hartung H-P, Fox EJ, Giovannoni G, et al. Alemtuzumab CARE-MS I 5-year follow-up: durable efficacy in the absence of continuous MS therapy. Neurology. 2017;89(11):1107–16.PubMedPubMedCentralGoogle Scholar
  58. 58.
    Durand-Dubief F, Marignier R, Berthezene Y, Cottin J, Nighoghossian N, Vukusic S. Spontaneous multiple cervical artery dissections after alemtuzumab. Mult Scler. 2019.
  59. 59.
    Azevedo CJ, Kutz C, Dix A, Boster A, Sanossian N, Kaplan J. Intracerebral haemorrhage during alemtuzumab administration. Lancet Neurol. 2019;18(4):329–31.PubMedGoogle Scholar
  60. 60.
    Ontaneda D, Moore A, Bakshi R, Zajicheck A, Kattan M, Fox R. Risk estimates of progressive multifocal leukoencephalopathy related to fingolimod. In: ECTRIMS Online Library. 2018. p. 1775.Google Scholar
  61. 61.
    Gold R, Kappos L, Arnold DL, Bar-Or A, Giovannoni G, Selmaj K, et al. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med. 2012;367(12):1098–107.PubMedGoogle Scholar
  62. 62.
    Moraes Machado MI, Cunha Matta AP, Apostolos Pereira SL, Alves-Leon SV, Marques VD, Gomes S, et al. Fingolimod prescribed for the treatment of multiple sclerosis in patients younger than age 18 years. Pediatr Neurol. 2015;53(2):166–8.PubMedGoogle Scholar
  63. 63.
    U.S. Food and Drug Administration. Press Announcements - FDA approves new oral drug to treat multiple sclerosis. Office of the Commissioner; [cited 2019 Apr 2]. Available from:
  64. 64.
    Kappos L, Bar-Or A, Cree BAC, Fox RJ, Giovannoni G, Gold R, et al. Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomized, phase 3 study. Lancet. 2018;391(10127):1263–73.PubMedGoogle Scholar
  65. 65.
    Vermersch P, Czlonkowska A, Grimaldi LME, Confavreux C, Comi G, Kappos L, et al. Teriflunomide versus subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis: a randomized, controlled phase 3 trial. Mult Scler. 2014;20(6):705–16.PubMedGoogle Scholar
  66. 66.
    Chitnis T, Tardieu M, Banwell B, Gücüyener K, Deiva K, Skripchenko N, et al. Evaluation of teriflunomide in children and adolescents with relapsing MS: TERIKIDS phase 3 study design, enrollment update, and baseline data (P4.354). Neurology. 2018;90(15 Supplement):4.354.Google Scholar
  67. 67.
    U.S. Food and Drug Admnistration. Press Announcements - FDA approves new oral treatment for multiple sclerosis. [Cited 2019 Apr 2]; Available from:
  68. 68.
    Leist TP, Comi G, Cree BAC, Coyle PK, Freedman MS, Hartung HP, et al. Effect of oral cladribine on time to conversion to clinically definite multiple sclerosis in patients with a first demyelinating event (ORACLE MS): a phase 3 randomized trial. Lancet Neurol. 2014;13(3):257–67.PubMedGoogle Scholar
  69. 69.
    Giovannoni G, Comi G, Cook S, Rammohan K, Rieckmann P, Sørensen PS, et al. A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis. N Engl J Med. 2010;362(5):416–26.PubMedGoogle Scholar
  70. 70.
    Rudick RA, Stuart WH, Calabresi PA, Confavreux C, Galetta SL, Radue E-W, et al. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med. 2006;354(9):911–23.PubMedGoogle Scholar
  71. 71.
    Polman CH, O’Connor PW, Havrdova E, Hutchinson M, Kappos L, Miller DH, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med. 2006;354(9):899–910.PubMedGoogle Scholar
  72. 72.
    Miller DH, Soon D, Fernando KT, MacManus DG, Barker GJ, Yousry TA, et al. MRI outcomes in a placebo-controlled trial of natalizumab in relapsing MS. Neurology. 2007;68(17):1390–401.PubMedGoogle Scholar
  73. 73.
    Arnal-Garcia C, Garcia-Montero MR, Malaga I, Millan-Pascual J, Oliva-Nacarino P, Ramio-Torrenta L, et al. Natalizumab use in pediatric patients with relapsing-remitting multiple sclerosis. Eur J Paediatr Neurol. 2013;17(1):50–4.PubMedGoogle Scholar
  74. 74.
    Ghezzi A, Pozzilli C, Grimaldi LME, Brescia Morra V, Bortolon F, Capra R, et al. Safety and efficacy of natalizumab in children with multiple sclerosis. Neurology. 2010;75(10):912–7.PubMedGoogle Scholar
  75. 75.
    Kean JM, Rao S, Wang M, Garcea RL. Seroepidemiology of human polyomaviruses. PLoS Pathog. 2009;5(3):e1000363.PubMedPubMedCentralGoogle Scholar
  76. 76.
    Huppke P, Hummel H, Ellenberger D, Pfeifenbring S, Stark W, Huppke B, et al. JC virus antibody status in a pediatric multiple sclerosis cohort: prevalence, conversion rate and influence on disease severity. Mult Scler. 2015;21(4):382–7.PubMedGoogle Scholar
  77. 77.
    Trampe AK, Hemmelmann C, Stroet A, Haghikia A, Hellwig K, Wiendl H, et al. Anti-JC virus antibodies in a large German natalizumab-treated multiple sclerosis cohort. Neurology. 2012;78(22):1736–42.PubMedGoogle Scholar
  78. 78.
    Hauser SL, Waubant E, Arnold DL, Vollmer T, Antel J, Fox RJ, et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med. 2008;358(7):676–88.PubMedGoogle Scholar
  79. 79.
    Naismith RT, Piccio L, Lyons JA, Lauber J, Tutlam NT, Parks BJ, et al. Rituximab add-on therapy for breakthrough relapsing multiple sclerosis: a 52-week phase II trial. Neurology. 2010;74(23):1860–7.PubMedPubMedCentralGoogle Scholar
  80. 80.
    Spelman T, Frisell T, Piehl F, Hillert J. Comparative effectiveness of rituximab relative to IFN-beta or glatiramer acetate in relapsing-remitting MS from the Swedish MS registry. Mult Scler. 2018;24(8):1087–95.PubMedGoogle Scholar
  81. 81.
    Cohen JA, Coles AJ, Arnold DL, Confavreux C, Fox EJ, Hartung HP, et al. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomized controlled phase 3 trial. Lancet. 2012;380(9856):1819–28.PubMedGoogle Scholar
  82. 82.
    Das B, Dimas V, Guleserian K, Lacelle C, Anton K, Moore L, et al. Alemtuzumab (Campath-1H) therapy for refractory rejections in pediatric heart transplant recipients. Pediatr Transplant. 2017;21(1).Google Scholar
  83. 83.
    Kim IK, Choi J, Vo AA, Kang A, Patel M, Toyoda M, et al. Safety and efficacy of alemtuzumab induction in highly sensitized pediatric renal transplant recipients. Transplantation. 2017;101(4):883–9.PubMedGoogle Scholar
  84. 84.
    Kaabak MM, Babenko NN, Samsonov DV, Sandrikov VA, Maschan AA, Zokoev AK. Alemtuzumab induction in pediatric kidney transplantation. Pediatr Transplant. 2013;17(2):168–78.PubMedPubMedCentralGoogle Scholar
  85. 85.
    Muraro PA, Douek DC, Packer A, Chung K, Guenaga FJ, Cassiani-Ingoni R, et al. Thymic output generates a new and diverse TCR repertoire after autologous stem cell transplantation in multiple sclerosis patients. J Exp Med. 2005;201(5):805–16.PubMedPubMedCentralGoogle Scholar
  86. 86.
    Darlington PJ, Touil T, Doucet J-S, Gaucher D, Zeidan J, Gauchat D, et al. Diminished Th17 (not Th1) responses underlie multiple sclerosis disease abrogation after hematopoietic stem cell transplantation. Ann Neurol. 2013;73(3):341–54.PubMedGoogle Scholar
  87. 87.
    Sormani MP, Muraro PA, Saccardi R, Mancardi G. NEDA status in highly active MS can be more easily obtained with autologous hematopoietic stem cell transplantation than other drugs. Mult Scler. 2017;23(2):201–4.PubMedGoogle Scholar
  88. 88.
    • Burman J, Kirgizov K, Carlson K, Badoglio M, Mancardi GL, De Luca G, et al. Autologous hematopoietic stem cell transplantation for pediatric multiple sclerosis: a registry-based study of the Autoimmune Diseases Working Party (ADWP) and Pediatric Diseases Working Party (PDWP) of the European Society for Blood and Marrow Transplant. Bone Marrow Transplant. 2017;52(8):1133–7 The only trial of hematopoetic stem cell transplantation in children with MS.PubMedGoogle Scholar
  89. 89.
    Freedman MS, Bar-Or A, Atkins HL, Karussis D, Frassoni F, Lazarus H, et al. The therapeutic potential of mesenchymal stem cell transplantation as a treatment for multiple sclerosis: consensus report of the International MSCT Study Group. Mult Scler. 2010;16(4):503–10.PubMedGoogle Scholar
  90. 90.
    Scolding NJ, Pasquini M, Reingold SC, Cohen JA. Cell-based therapeutic strategies for multiple sclerosis. Brain. 2017;140(11):2776–96.PubMedPubMedCentralGoogle Scholar
  91. 91.
    Tur C, Moccia M, Barkhof F, Chataway J, Sastre-Garriga J, Thompson AJ, et al. Assessing treatment outcomes in multiple sclerosis trials and in the clinical setting. Nat Rev Neurol. 2018:3–5.Google Scholar
  92. 92.
    Rotstein DL, Healy BC, Malik MT, Chitnis T, Weiner HL. Evaluation of no evidence of disease activity in a 7-year longitudinal multiple sclerosis cohort. JAMA Neurol. 2015;72(2):152–8.PubMedGoogle Scholar
  93. 93.
    Kurtzke JF. Disability rating scales in multiple sclerosis. Ann N Y Acad Sci. 1983;436(1):347–60.Google Scholar
  94. 94.
    Whitaker JN, McFarland HF, Rudge P, Reingold SC. Outcomes assessment in multiple sclerosis trials. Mult Scler. 1995;1(1):37–47.PubMedGoogle Scholar
  95. 95.
    Noseworthy JH, Vandervoort MK, Wong CJ, Ebers GC. Interrater variability with the Expanded Disability Status Scale (EDSS) and Functional Systems (FS) in a multiple sclerosis clinical trial. The Canadian Cooperation MS Study Group. Neurology. 1990;40(6):971–5.PubMedGoogle Scholar
  96. 96.
    •• Waldman AT, Chahin S, Lavery AM, Liu G, Banwell BL, Liu GT, et al. Binocular low-contrast letter acuity and the symbol digit modalities test improve the ability of the Multiple Sclerosis Functional Composite to predict disease in pediatric multiple sclerosis. Mult Scler Relat Disord. 2016;10(2016):73–8 Important paper on the development of clinical outcome measures in pediatric multiple sclerosis.PubMedPubMedCentralGoogle Scholar
  97. 97.
    Fischer JS, Rudick RA, Cutter GR, Reingold SC. The Multiple Sclerosis Functional Composite measure (MSFC): an integrated approach to MS clinical outcome assessment. Mult Scler J. 1999;5(4):244–50.Google Scholar
  98. 98.
    Benedict RHB, Deluca J, Phillips G, Larocca N, Hudson LD. Validity of the Symbol Digit Modalities Test as a cognition performance outcome measure for multiple sclerosis. Mult Scler J. 2017;23(5):721–33.Google Scholar
  99. 99.
    Novakova L, Zetterberg H, Sundstrom P, Axelsson M, Khademi M, Gunnarsson M, et al. Monitoring disease activity in multiple sclerosis using serum neurofilament light protein. Neurology. 2017;89(22):2230–7.PubMedPubMedCentralGoogle Scholar
  100. 100.
    •• van der Vuurst de Vries RM, Wong YYM, Mescheriakova JY, van Pelt ED, Runia TF, Jafari N, et al. High neurofilament levels are associated with clinically definite multiple sclerosis in children and adults with clinically isolated syndrome. Mult Scler J. 2018;1–10. Diagnostic value of NfL in children with an isolated demyelinating event.Google Scholar
  101. 101.
    Mar S, Piccio L. CSF Neurofilament light chain levels as a biomarker for pediatric demyelinating diseases (P5.349). Neurology. 2016;86(16 Supplement):5.349.Google Scholar
  102. 102.
    Reinert M, Barro C, Michalak Z, Bruck W, Huppke P, Kropshofer H, et al. Neurofilament light chain is a useful biomarker in paediatric multiple sclerosis. ECTRIMS online library 2018. p. 666.Google Scholar
  103. 103.
    Lambe J, Murphy OC, Saidha S. Can optical coherence tomography be used to guide treatment decisions in adult or pediatric multiple sclerosis? Curr Treat Options Neurol. 2018;20(4).Google Scholar
  104. 104.
    Graves JS, Chohan H, Cedars B, Arnow S, Yiu H, Waubant E, et al. Sex differences and subclinical retinal injury in pediatric-onset MS. Mult Scler. 2017;23(3):447–55.PubMedGoogle Scholar
  105. 105.
    Huhn K, Lammer R, Oberwahrenbrock T, Lammer A, Waschbisch A, Gosar D, et al. Optical coherence tomography in patients with a history of juvenile multiple sclerosis reveals early retinal damage. Eur J Neurol. 2015;22(1):86–92.PubMedGoogle Scholar
  106. 106.
    Sadaka Y, Verhey LH, Shroff MM, Branson HM, Arnold DL, Narayanan S, et al. 2010 McDonald criteria for diagnosing pediatric multiple sclerosis. Ann Neurol. 2012;72(2):211–23.PubMedGoogle Scholar
  107. 107.
    Thompson AJ, Banwell BL, Barkhof F, Carroll WM, Coetzee T. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol. 2018;17(2):162–73.PubMedPubMedCentralGoogle Scholar
  108. 108.
    Krupp LB, Tardieu M, Amato MP, Banwell B, Chitnis T, Dale RC, et al. International Pediatric Multiple Sclerosis Study Group criteria for pediatric multiple sclerosis and immune-mediated central nervous system demyelinating disorders: revisions to the 2007 definitions. Mult Scler J. 2013;19(10):1261–7.Google Scholar
  109. 109.
    Maggi P, Absinta M, Grammatico M, Vuolo L, Emmi G, Carlucci G, et al. Central vein sign differentiates multiple sclerosis from central nervous system inflammatory vasculopathies. Ann Neurol. 2018;83(2):283–94.PubMedPubMedCentralGoogle Scholar
  110. 110.
    Sinnecker T, Wuerfel E, Cerda Fuertes N, Meier D, Derfuss T, Gartner J, et al. The central vein sign in paediatric-onset multiple sclerosis. ECTRIMS online library 2018. P.346.Google Scholar
  111. 111.
    Sati P, Oh J, Todd Constable R, Evangelou N, Guttmann CRG, Henry RG, et al. The central vein sign and its clinical evaluation for the diagnosis of multiple sclerosis: a consensus statement from the North American Imaging in Multiple Sclerosis Cooperative. Nat Rev Neurol. 2016;12(12):714–22.PubMedGoogle Scholar
  112. 112.
    Young NP, Weinshenker BG, Parisi JE, Scheithauer B, Giannini C, Roemer SF, et al. Perivenous demyelination: association with clinically defined acute disseminated encephalomyelitis and comparison with pathologically confirmed multiple sclerosis. Brain. 2010;133(Pt 2):333–48.PubMedPubMedCentralGoogle Scholar
  113. 113.
    Thannhauser JE, Mah JK, Metz LM. Adherence of adolescents to multiple sclerosis disease-modifying therapy. Pediatr Neurol. 2009;41(2):119–23.PubMedGoogle Scholar
  114. 114.
    Tremlett H, Van der Mei I, Pittas F, Blizzard L, Paley G, Dwyer T, et al. Adherence to the immunomodulatory drugs for multiple sclerosis: contrasting factors affect stopping drug and missing doses. Pharmacoepidemiol Drug Saf. 2008;17(6):565–76.PubMedGoogle Scholar
  115. 115.
    McKay KA, Tremlett H, Patten SB, Fisk JD, Evans C, Fiest K, et al. Determinants of non-adherence to disease-modifying therapies in multiple sclerosis: a cross-Canada prospective study. Mult Scler. 2017;23(4):588–96.PubMedGoogle Scholar
  116. 116.
    Lulu S, Julian L, Shapiro E, Hudson K, Waubant E. Treatment adherence and transitioning youth in pediatric multiple sclerosis. Mult Scler Relat Disord. 2014;3(6):689–95.PubMedPubMedCentralGoogle Scholar
  117. 117.
    Schwartz CE, Grover SA, Powell VE, Noguera A, Mah JK, Mar S, et al. Risk factors for non-adherence to disease-modifying therapy in pediatric multiple sclerosis. Mult Scler J. 2018;24(2):175–85.Google Scholar
  118. 118.
    Yeh EA, Grover SA, Powell VE, Alper G, Banwell BL, Edwards K, et al. Impact of an electronic monitoring device and behavioral feedback on adherence to multiple sclerosis therapies in youth: results of a randomized trial. Qual Life Res. 2017;26(9):2333–49.PubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  • Gabrielle Macaron
    • 1
  • Jenny Feng
    • 1
  • Manikum Moodley
    • 2
  • Mary Rensel
    • 1
    Email author
  1. 1.Mellen Center for Multiple Sclerosis, Cleveland ClinicClevelandUSA
  2. 2.Center for Pediatric Neurosciences, Cleveland ClinicClevelandUSA

Personalised recommendations